1 / 53

“Cancer2006: From molecular biology processes to tumor-tailored therapy” 20-24, august, 2006 High Tatras, Slovakia

“Cancer2006: From molecular biology processes to tumor-tailored therapy” 20-24, august, 2006 High Tatras, Slovakia. THE INVITED SPEAKERS – BRIEF SCIENTIFIC PROFILE. KEYNOTE LECTURE No.1. Andy Futreal, PhD. Co-head of the Cancer Genome Project Wellcome Trust Sanger Institute

Olivia
Download Presentation

“Cancer2006: From molecular biology processes to tumor-tailored therapy” 20-24, august, 2006 High Tatras, Slovakia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “Cancer2006: From molecular biology processes to tumor-tailored therapy”20-24, august, 2006 High Tatras, Slovakia THE INVITED SPEAKERS – BRIEF SCIENTIFIC PROFILE

  2. KEYNOTE LECTURE No.1 Andy Futreal, PhD. Co-head of the Cancer Genome Project Wellcome Trust Sanger Institute Hinxton, United Kingdom Title of the lecture: The WTSI Cancer genome Project: understanding the targets

  3. PUBLICATIONS: • Wooster R, Futreal AP, Stratton MR. Sequencing Analysis of BRAF Mutations in Human Cancers. Methods Enzymol. 2005 • Futreal PA, Wooster R, Stratton MR. Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. Cold Spring Harb Symp Quant Biol. 2005 • Stratton MR, Wooster RW, Futreal PA. The BRAF gene is frequently mutated in malignant melanoma. J Drugs Dermatol. 2004 • Blow M, Futreal PA, Wooster R, Stratton MR.A survey of RNA editing in human brain. Genome Res. 2004 • Stratton MR, Futreal PA. Cancer: understanding the target. Nature. 2004 • Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR.A census of human cancer genes.Nat Rev Cancer. 2004

  4. KEYNOTE LECTURE No. 2 Prof. Josef Jiricny Director, Institute of Molecular Cancer Research University of Zürich, Switzerland Title of the lecture: Towards the therapy of tumors with microsatellite instability

  5. PUBLICATIONS: • Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006 • Cejka P, Stojic L, Marra G, Jiricny J. Is mismatch repair really required for ionizing radiation-induced DNA damage signaling? Nat Genet 2004 • Jiricny J. An APE that proofreads. Nature 2002 • Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, Truong O, Hsuan JJ, Jiricny J.GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 1995 • Brown TC, Jiricny J. Different base/base mispairs are corrected with different efficiencies and specificities in monkey kidney cells. Cell. 1988

  6. KEYNOTE LECTURE No. 3 Ivan Horak, MD. Vice - Director Enzon Pharmaceuticals, Inc. Research and Development New Jersey, USA Title of the lecture: Targeted therapy: from bench to bedside

  7. PUBLICATIONS: • Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.Clin Cancer Res. 2005 • Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.Nat Med. 2005 • Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Technol Cancer Res Treat. 2005 • Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.Int J Cancer. 1997 • Horak ID, Popovic M, Horak EM, Lucas PJ, Gress RE, June CH, Bolen JB.No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120.Nature. 1990

  8. Session 1: RETROVIRUSES IN MALIGNANT TRANSFORMATION Prof. Kathleen Boris-Lawrie Department of Veterinary Sciences The Ohio State University, USA Title of the lecture: New insight into translational regulation of growth control genes: lessons derived from study of retroviruses

  9. PUBLICATIONS: • Younis I, Boris-Lawrie K, Green PL. Human T-cell leukemia virus open reading frame II encodes a posttranscriptional repressor that is recruited at the level of transcription. J Virol. 2006 • Altanerova V, Holicova D, Kucerova L, Altaner C, Lairmore MD, Boris-Lawrie K. Long-term infection with retroviral structural gene vector provides protection againstbovine leukemia virusdisease in rabbits. Virology. 2004 • Roberts TM, Boris-Lawrie K. Primary sequence and secondary structure motifs in spleen necrosis virus RU5 confer translational utilization of unspliced human immunodeficiency virus type 1 reporter RNA. J Virol. 2003 • Butsch M, Boris-Lawrie K. Destiny of unspliced retroviral RNA: ribosome and/or virion? J Virol. 2002 • Butsch M, Hull S, Wang Y, Roberts TM, Boris-Lawrie K. The 5' RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production. J Virol. 1999

  10. Session 1: RETROVIRUSES IN MALIGNANT TRANSFORMATION Prof. Richard Kettmann Faculty of Agronomy, Gembloux, Belgium Title of the lecture: Metabolic pathways involved in transformational induced by oncoviral Tax proteins

  11. PUBLICATIONS: • Debacq C, Heraud JM, Asquith B, Bangham C, Merien F, Moules V, Mortreux F, Wattel E, Burny A, Kettmann R, Kazanji M, Willems L. Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1. Oncogene. 2005 • Twizere JC, Lefebvre L, Collete D, Debacq C, Urbain P, Heremans H, Jauniaux JC, Burny A, Willems L, Kettmann R. The homeobox protein MSX2 interacts with tax oncoproteins and represses their transactivation activity. J Biol Chem. 2005 • Dequiedt F, Van Lint J, Lecomte E, Van Duppen V, Seufferlein T, Vandenheede JR, Wattiez R, Kettmann R. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J Exp Med. 2005 • Poturnajova M, Altanerov V, Kettmann R, Feikova S, Hlubinova K, Balazovjech I, Breza J, Fodo G, Knotek J, Matoska J, Podobov M, Altaner C. Germline mutation of the RET proto-oncogene in members of Slovak families with multiple endocrine neoplasia 2.Neoplasma 2001

  12. Session 1: RETROVIRUSES IN MALIGNANT TRANSFORMATION Prof. Jan Svoboda Professor of cellular and molecular biology CU Institute of Molecular Genetics Prague, Czech Republic Title of the lecture: Cell defense against retroviruses

  13. PUBLICATIONS: • J. Svoboda: Presence of chicken tumour virus in the sarcoma of the adult rat inoculated after birth with Rous sarcoma tissue. Nature 1960 • J. Svoboda: Molecular biology of cell nonpermissiveness to retroviruses. Has the time come? Gene 1998 • J. Svoboda, J. Geryk, D. Elleder: Heterogeneous pathogenicity of retroviruses: Lessons from birds, primates, and rodents. Adv. Canc. Res. 2003 • Hejnar J, Hajkova P, Plachy J, Elleder D, Stepanets V, Svoboda J. CpG island protects Rous sarcoma virus-derived vectors integrated into nonpermissive cells from DNA methylation and transcriptional suppression.Proc Natl Acad Sci U S A. 2001

  14. Session 2: MOLECULAR PATHOGENESIS OF CANCER Karl Heinimann, PhD. University of Basel Switzerland Title of the lecture: The mechanism of inactivation of the wild-type allele in hereditary cancers such as FAP and HNPCC

  15. PUBLICATIONS: • Zhang J, Lindroos A, Ollila S, Russell A, Marra G, Mueller H, Peltomaki P, Plasilova M, Heinimann K. Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res. 2006 • Westphalen AA, Russell AM, Buser M, Berthod CR, Hutter P, Plasilova M, Mueller H, Heinimann K. Evidence for genetic anticipation in hereditary non-polyposis colorectal cancer. Hum Genet. 2005 • Crabtree M, Sieber OM, Lipton L, Hodgson SV, Lamlum H, Thomas HJ, Neale K, Phillips RK, Heinimann K, Tomlinson IP. Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients. Oncogene. 2003 • Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L, Hodgson S, Thomas HJ, Neale K, Phillips RK, Farrington SM, Dunlop MG, Mueller HJ, Bisgaard ML, Bulow S, Fidalgo P, Albuquerque C, Scarano MI, Bodmer W, Tomlinson IP, Heinimann K.Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or "multiple" colorectal adenomas. Proc Natl Acad Sci U S A. 2002

  16. Session 2: MOLECULAR PATHOGENESIS OF CANCER Linda Wolff, PhD. Chief, Leukemogenesis Section Laboratory of Cellular Oncology, CCR National Cancer Institute, NIH Bethesda, USA Title of the lecture: Cyclin-dependent kinase inhibitor p15INK4B in leukemia and normal hematopoiesis

  17. PUBLICATIONS: • Hu X, Bies J,Wolff L. Interferon beta increases c-Myc proteolysis in mouse monocyte/macrophage leukemia cells. Leuk Res. 2005 • Schmidt M, Bies J, Tamura T, Ozato K, Wolff L. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood. 2004 • Wolff L, Garin MT, Koller R, Bies J, Liao W, Malumbres M, Tessarollo L, Powell D, Perella C. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene. 2003 • Haviernik P, Schmidt M, Hu X, Wolff L. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc. Oncogene. 2003 • Schmidt M, Koller R, Haviernik P, Bies J, Maciag K, Wolff L. Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation.Oncogene. 2001

  18. Session 2: MOLECULAR PATHOGENESIS OF CANCER Juraj Bies, PhD. National Cancer Institute, NIH Bethesda, USA Title of the lecture: Leukemogenesis and c-Myb: story of a tightly regulated transcriptional regulator

  19. PUBLICATIONS: • Markus J, Feikova S, Sramko M, Wolff L, Bies J. Proliferation-linked expression of the novel murine gene m4mbt encoding a nuclear zinc finger protein with four mbt domains.Gene. 2003 • Bies J, Markus J, Wolff L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem. 2002 • Bies J, Feikova S, Markus J, Wolff L. Phosphorylation-dependent conformation and proteolytic stability of c-Myb. Blood Cells Mol Dis. 2001 • Bies J, Feikova S, Bottaro DP, Wolff L. Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases. Oncogene. 2000 • Hu X, Bies J, Wolff L. Interferon beta increases c-Myc proteolysis in mouse monocyte/macrophage leukemia cells. Leuk Res. 2005

  20. Session 3: DNA DAMAGE AND REPAIR PROCESSES I. Bennett Van Houten, PhD. Chief, Program Analysis Branch & Investigator in the Laboratory of Molecular Genetics National Institutes of Environmental Health Sciences Research Triangle Park, NC, USA Title of the lecture: In search of damage: Structure-function studies of nucleotide excision repair

  21. PUBLICATIONS: • Santos JH, Meyer JN, Van Houten B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis.Hum Mol Genet. 2006 • Truglio JJ, Karakas E, Rhau B, Wang H, Dellavecchia MJ, Van Houten B, Kisker C. Structural basis for DNA recognition and processing by UvrB. Nat Struct Mol Biol. 2006 • Truglio JJ, Rhau B, Croteau DL, Wang L, Skorvaga M, Karakas E, DellaVecchia MJ, Wang H, Van Houten B, Kisker C. Structural insights into the first incision reaction during nucleotide excision repair. EMBO J. 2005 • Skorvaga M, DellaVecchia MJ, Croteau DL, Theis K, Truglio JJ, Mandavilli BS, Kisker C, Van Houten B. Identification of residues within UvrB that are important for efficient DNA binding and damage processing. J Biol Chem. 2004 • Dubaele S, Proietti De Santis L, Bienstock RJ, Keriel A, Stefanini M, Van Houten B, Egly JM. Basal transcription defect discriminates between xeroderma pigmentosum and trichothiodystrophy in XPD patients. Mol Cell. 2003

  22. Session 3: DNA DAMAGE AND REPAIR PROCESSES I. Prof. Jiri Lukas Institute of Cancer Biology for Genotoxic Stress Resarch Danish Cancer Society, Copenhagen, Denmark Title of the lecture: Cellular response to DNA damage: Molecular mechanism and spatio-temporal organization in living mammaliancells

  23. PUBLICATIONS: • Bartek J, Lukas J. Cell biology. The stress of finding NEMO.Science. 2006 • Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005 • Lukas J, Bartek J. Cell division: the heart of the cycle. Nature. 2004 • Lukas J, Bartek J. Watching the DNA repair ensemble dance. Cell. 2004 • Bartek J, Lukas J. Are all cancer genes equal? Nature. 2001 • Bartek J, Lukas J.Cell cycle. Order from destruction. Science. 2001.

  24. Session 3: DNA DAMAGE AND REPAIR PROCESSES I. Mark O’Driscoll, PhD. Sussex Centre for Genome Damage and Stability University of Sussex Falmer, Brighton Title of the lecture: DNA double strands break repair and cancer predisposition: Lessons from human syndromes

  25. PUBLICATIONS: • O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet. 2006 • Alderton GK, Joenje H, Varon R, Borglum AD, Jeggo PA, O'Driscoll M. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum Mol Genet. 2004 • O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair (Amst). 2004 • Gennery AR, O'Driscoll M. Unravelling the web of DNA repair disorders.Clin Exp Immunol. 2003 • O'Driscoll M, Jeggo PA. Clinical impact of ATR checkpoint signalling failure in humans. Cell Cycle. 2003

  26. Session 4: DNA DAMAGE AND REPAIR PROCESSES II. Miroslav Chovanec, PhD. Senior investigator Laboratory of Molecular Genetics Cancer Research Institute of Slovak Academy of Sciences Bratislava Title of the lecture: Cellular response to oxidative DNA damage in Saccharomyces cerevisiae

  27. PUBLICATIONS: • Dudas A, Markova E, Vlasakova D, Kolman A, Bartosova Z, Brozmanova J, Chovanec M. The Escherichia coli RecA protein complements recombination defective phenotype of the Saccharomyces cerevisiae rad52 mutant cells.Yeast. 2003 • Dudas A, Chovanec M. DNA double-strand break repair by homologous recombination.Mutat Res. 2004 • Dudasova Z, Dudas A, Chovanec M. Non-homologous end-joining factors of Saccharomyces cerevisiae. FEMS Microbiol Rev. 2004 • Brozmanova J, Vlckova V, Chovanec M. How heterologously expressed Escherichia coli genes contribute to understanding DNA repair processes in Saccharomyces cerevisiae.Curr Genet. 2004 • Kysela B, Chovanec M, Jeggo PA. Phosphorylation of linker histones by DNA-dependent protein kinase is required for DNA ligase IV-dependent ligation in the presence of histone H1. Proc Natl Acad Sci U S A. 2005

  28. Session 4: DNA DAMAGE AND REPAIR PROCESSES II. Miroslav Pirsel, PhD. Head of Laboratory of Molecular Genetics Cancer Research Institute of Slovak Academy of Sciences Bratislava Title of the lecture: Repair of oxidative DNA damage in the helicase mutants

  29. PUBLICATIONS: • Wassermann K, Pirsel M, Bohr VA. Overexpression of metallothionein in Chinese hamster ovary cells and its effect on nitrogen mustard-induced cytotoxicity: role of gene-specific damage and repair.Cancer Res. 1992 • Pirsel M, Bohr VA. Methyl methanesulfonate adduct formation and repair in the DHFR gene and in mitochondrial DNA in hamster cells.Carcinogenesis. 1993 • Sedliakova M, Slezarikova V, Masek F, Vizvaryova M, Pirsel M. Role of DNA polymerase II in the tolerance of thymine dimers remaining unexcised in UV-irradiated Escherichia coli exposed to pre-UV nutritional stress. J Photochem Photobiol B. 2001 • Hall H, Gursky J, Nicodemou A, Rybanska I, Kimlickova E, Pirsel M. Characterization of ERCC3 mutations in the Chinese hamster ovary 27-1, UV24 and MMC-2 cell lines.Mutat Res. 2006 • Pirsel M, Chovanec M, Dudas A, Kleibl K, Van Houten B. Fourth DNA repair workshop on DNA damage and repair: mechanisms and biological consequences Smolenice Castle, 2-5 May 2004. DNA Repair (Amst). 2004

  30. Session 5: CANCER GENETICS Minna Nystrom, PhD. Senior scientist & Research Manager Department of Biological and Environmental Sciences University of Helsinki, Finland Title of the lecture: Functional significance and clinical phenotype of non-truncating inherited mismatch repair gene variants

  31. PUBLICATIONS: • Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lonnqvist KE, Holinski-Feder E, Sutter C, McKinnon W, Duraisamy S, Gerdes AM, Peltomaki P, Kohonen-Ccorish M, Mangold E, Macrae F, Greenblatt M, de la Chapelle A, Nystrom M. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.Gastroenterology. 2005 • Kariola R, Abdel-Rahman WM, Ollikainen M, Butzow R, Peltomaki P, Nystrom M.APC and beta-catenin protein expression patterns in HNPCC-related endometrial and colorectal cancers. Fam Cancer. 2005 • Nystrom-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Jarvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B, et al. Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med. 1995 • Nystrom-Lahti M, Sistonen P, Mecklin JP, Pylkkanen L, Aaltonen LA, Jarvinen H, Weissenbach J, de la Chapelle A, Peltomaki P. Close linkage to chromosome 3p and conservation of ancestral founding haplotype in hereditary nonpolyposis colorectal cancer families. Proc Natl Acad Sci U S A. 1994 • Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993

  32. Session 5: CANCER GENETICS Vladimir Zajac, PhD. Head of Laboratory of Cancer Genetics Cancer Research Institute of Slovak Academy of Sciences Bratislava Title of the lecture: FAP and HBOC: two players in one playground

  33. PUBLICATIONS: • Ciernikova S, Tomka M, Kovac M, Stevurkova V, Zajac V. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma. 2006 • Kovac M, Tomka M, Ciernikova S, Stevurkova V, Valachova A, Zajac V. Multiple gynecologic tumors as rare associated phenotypes of FAP/Gardner syndrome in a family with the novel germline mutation in the APC gene. Clin Genet. 2006 • Mego M, Koncekova R, Mikuskova E, Drgona L, Ebringer L, Demitrovicova L, Nemova I, Trupl J, Mardiak J, Koza I, Zajac V. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer. 2006 • Anker P, Zajac V, Lyautey J, Lederrey C, Dunand C, Lefort F, Mulcahy H, Heinemann J, Stroun M. Transcession of DNA from bacteria to human cells in culture: a possible role in oncogenesis. Ann N Y Acad Sci. 2004 • Zajac V, Kirchhoff T, Levy ER, Horsley SW, Miller A, Steichen-Gersdorf E, Monaco AP. Characterisation of X;17(q12;p13) translocation breakpoints in a female patient with hypomelanosis of Ito and choroid plexus papilloma.Eur J Hum Genet. 1997

  34. Session 5: CANCER GENETICS Zdena Bartosova, PhD. Senior investigator Laboratory of Molecular Genetics Cancer Research Institute of Slovak Academy of Sciences Bratislava Title of the lecture: Advances in molecular diagnostics of hereditary non-polyposis colorectal cancer in Slovakia

  35. PUBLICATIONS: • Venema J, Bartosova Z, Natarajan AT, van Zeeland AA, Mullenders LH. Transcription affects the rate but not the extent of repair of cyclobutane pyrimidine dimers in the human adenosine deaminase gene. J Biol Chem. 1992 • Bartosova Z, Pirsel M, Reinhold W, Stetler-Stevenson M, Zajac-Kaye M, May A, Horak ID, Bohr VA. Gene-specific repair in human CD4+ lymphocytes reflects transcription and proliferation. Mutat Res. 1996 • Marra G, D'Atri S, Corti C, Bonmassar L, Cattaruzza MS, Schweizer P, Heinimann K, Bartosova Z, Nystrom-Lahti M, Jiricny J . Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci U S A. 2001 • Bartosova Z, Fridrichova I, Bujalkova M, Wolf B, Ilencikova D, Krizan P, Hlavcak P, Palaj J, Lukac L, Lukacova M, Boor A, Haider R, Jiricny J, Nystrom-Lahti M, Marra G. Novel MLH1 and MSH2 germline mutations in the first HNPCC families identified in Slovakia. Hum Mutat. 2003 • Zavodna K, Bujalkova M, Krivulcik T, Alemayehu A, Skorvaga M, Marra G, Fridrichova I, Jiricny J, Bartosova Z.Novel and recurrent germline alterations in the MLH1 and MSH2 genes identified in hereditary nonpolyposis colorectal cancer patients in Slovakia. Neoplasma 2006

  36. Session 6: TUMOR CELL SIGNALING AND CELL DEATH Prof. Gerhard Christofori Institute of Biochemistry and Genetics University of Basel, Switzerland Title of the lecture: Cell adhesion in tumor invasion and metastasis

  37. PUBLICATIONS: • Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G.Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006 • Kopfstein L, Christofori G.Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci. 2006 • Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004 • Gannon G, Mandriota SJ, Cui L, Baetens D, Pepper MS, Christofori G. Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res. 2002 • Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol. 2001

  38. Session 6: TUMOR CELL SIGNALING AND CELL DEATH Jozef Bizik, PhD., DsC. Senior investigator Laboratory of Molecular Oncology Cancer Research Institute of Slovak Academy of Sciences Bratislava Title of the lecture: Nemosis – prospective cell based cancer therapy

  39. PUBLICATIONS: • Kankuri E, Cholujova D, Comajova M, Vaheri A, Bizik J. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res. 2005 • Bizik J, Kankuri E, Ristimaki A, Taieb A, Vapaatalo H, Lubitz W, Vaheri A. Cell-cell contacts trigger programmed necrosis and induce cyclooxygenase-2 expression. Cell Death Differ. 2004 • Eleveld-Trancikova D, Kudela P, Majerciak V, Regendova M, Zelnik V, Pastorek J, Pastorekova S, Bizik J. Suppression subtractive hybridisation to isolate differentially expressed genes involved in invasiveness of melanoma cell line cultured under different conditions. Int J Oncol. 2002 • Vaheri A, Tapiovaara H, Myohanen H, Bizik J. Alpha 2-macroglobulin in the regulation of pericellular plasminogen activation of human tumor cells. Ann N Y Acad Sci. 1994 • Bizik J, Lizonova A, Grofova M, Matoska J, Dore JF, Bertrand S, Blasko M, Vaheri A. Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation.Cancer Res. 1989

  40. Session 7: CARCINOGENESIS / ANTICARCINOGENESIS I. Prof. Leonard Mullenders Department of Toxicogenetics Leiden University Medical Center Leiden, The Netherlands Title of the lecture: From initial DNA damage to cancer: Lessons from mouse models

  41. PUBLICATIONS: • Alekseev S, Kool H, Rebel H, Fousteri M, Moser J, Backendorf C, de Gruijl FR, Vrieling H, Mullenders LH. Enhanced DDB2 expression protects mice from carcinogenic effects of chronic UV-B irradiation. Cancer Res. 2005 • Fousteri M, van Hoffen A, Vargova H, Mullenders LH. Repair of DNA lesions in chromosomal DNA impact of chromatin structure and Cockayne syndrome proteins. DNA Repair (Amst). 2005 • Riou L, Eveno E, van Hoffen A, van Zeeland AA, Sarasin A, Mullenders LH. Differential repair of the two major UV-induced photolesions in trichothiodystrophy fibroblasts. Cancer Res. 2004 • Buterin T, Hess MT, Gunz D, Geacintov NE, Mullenders LH, Naegeli H. Trapping of DNA nucleotide excision repair factors by nonrepairable carcinogen adducts. Cancer Res. 2002 • Volker M, Mone MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W, Hoeijmakers JH, van Driel R, van Zeeland AA, Mullenders LH. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell. 2001

  42. Session 7: CARCINOGENESIS / ANTICARCINOGENESIS I. Prof. Andrew Collins Department of Nutrition, University of Oslo Blindern, Oslo, Norway Title of the lecture: Cancer prevention by fruits and vegetables; not just a question for antioxidants

  43. PUBLICATIONS: • Dusinska M, Dzupinkova Z, Wsolova L, Harrington V, Collins AR. Possible involvement of XPA in repair of oxidative DNA damage deduced from analysis of damage, repair and genotype in a human population study. Mutagenesis. 2006 • Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005 • Collins AR. Antioxidant intervention as a route to cancer prevention. Eur J Cancer. 2005 • Gedik CM, Grant G, Morrice PC, Wood SG, Collins AR. Effects of age and dietary restriction on oxidative DNA damage, antioxidant protection and DNA repair in rats. Eur J Nutr. 2005 • Collins AR, Ferguson LR. Nutrition and carcinogenesis.Mutation Research. 2004

  44. Session 8: CARCINOGENESIS / ANTICARCINOGENESIS II. Prof. Krzysztof Szyfter Institute of Human Genetics Polish Academy of Sciences Poznan, Poland Title of the lecture: Modulation of laryngeal cancer incidence and progression by gene polymorphism

  45. PUBLICATIONS: • Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K. The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett. 2005 • Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 2005 • Kujawski M, Jarmuz M, Rydzanicz M, Szukala K, Wierzbicka M, Grenman R, Golusinski W, Szyfter K. Frequent chromosome Y loss in primary, second primary and metastatic squamous cell carcinomas of the head and neck region. Cancer Lett. 2004 • lasiak J, Jaloszynski P, Trzeciak A, Szyfter K. In vitro studies on the genotoxicity of the organophosphorus insecticide malathion and its two analogues. Mutat Res. 1999

  46. Session 9: TUMOR-TAILORED THERAPIES Geoffrey Margison, PhD Paterson Institute for Cancer Research senior investigator Manchester, United Kingdom Title of the lecture: DNA repair based strategies

  47. PUBLICATIONS: • Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006 • Margison GP, Heighway J, Pearson S, McGown G, Thorncroft MR, Watson AJ, Harrison KL, Lewis SJ, Rohde K, Barber PV, O'Donnell P, Povey AC, Santibanez-Koref MF. Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis. 2005 • Barvaux VA, Ranson M, Brown R, McElhinney RS, McMurry TB, Margison GP. Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther. 2004 • Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 2003

  48. Session 9: TUMOR-TAILORED THERAPIES Jan Sedlak, PhD. Deputy director and Head of Laboratory of Tumor Immunology of Cancer Research Institute of Slovak Academy of Sciences Bratislava Title of the lecture: A possible role of dietary chemopreventive compounds in tumor therapy

  49. PUBLICATIONS: • Bodo J, Jakubikova J, Chalupa I, Bartosova Z, Horakova K, Floch L, Sedlak J. Apoptotic effect of ethyl-4-isothiocyanatobutanoate is associated with DNA damage, proteasomal activity and induction of p53 and p21(cip1/waf1). Apoptosis. 2006 • Slamenova D, Horvathova E, Robichova S, Hrusovska L, Gabelova A, Kleibl K, Jakubikova J, Sedlak J. Molecular and cellular influences of butylated hydroxyanisole on Chinese hamster V79 cells treated with N-methyl-N'-nitro-N-nitrosoguanidine: antimutagenicity of butylated hydroxyanisole. Int J Oncol. 2005 • Jakubikova J, Sedlak J, Bacon J, Goldson A, Bao Y. Effects of MEK1 and PI3K inhibitors on allyl-, benzyl- and phenylethyl-isothiocyanate-induced G2/M arrest and cell death in Caco-2 cells. Environ Mol Mutagen. 2003 • Jakubikova J, Sedlak J, Bod'o J, Bao Y. Effect of isothiocyanates on nuclear accumulation of NF-kappaB, Nrf2, and thioredoxin in caco-2 cells. J Agric Food Chem. 2006 • Jakubikova J, Bao Y, Sedlak J. Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines.Anticancer Res. 2005

  50. Session 9: TUMOR-TAILORED THERAPIES Prof. Martin Brendel Universidade Estadual de Santa Cruz, Bahia, Brasil Title of the lecture: Tumor regression by antisense therapy against Plk1 and Bcl-2

More Related